Navigation Links
Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
Date:9/13/2012

TORRANCE, Calif., Sept. 13, 2012 /PRNewswire/ -- In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.  For a complete list of the clinical trial sites please visit http://www.clinicaltrials.gov (NCT01179217).

With the clinical trial already in progress, Emmaus Medical also announced that an interim subset of data was analyzed and submitted to the U.S. Food and Drug Administration (FDA) by an independent committee.  Currently, more than 190 of up to 225 patients are enrolled in the trial, and the company said it expects final data collection to be complete in 2013.

"During Sickle Cell Awareness month, we are reminded of the pain and suffering of those affected by this debilitating disease and the need for a widely available treatment," said Yutaka Niihara, M.D., MPH, founder and CEO of Emmaus Medical.  "Today, we believe Emmaus is the only company with a Phase III trial underway for a new sickle cell treatment. With research grants and through the generous support of friends and family over the past 20 years, we have progressed to the point where we are confident in our treatment and hopeful that it will be in the hands of patients worldwide in the not too distant future."

Click here to watch  a video of Dr. Niihara discussing the three things that everyone should know about sickle cell disease or visit: http://www.youtube.com/user/EmmausMedical.

Emmaus' patent-protected treatment, whose research was led by Dr. Niihara and investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, has orphan drug designation and Fast Track status in the United States and Orphan Medicinal Product designation in the European Union.

To discuss its research, Emmaus will be participating in the 40th Annual Sickle Cell Disease Association of America National Convention, from September 25 to 29 at the Baltimore Marriot Waterfront Hotel in Baltimore.

About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder causing red blood cells to become oxidized, forming rigid and sickled shaped cells that block small blood vessels.  The condition causes debilitating pain crises and organ damages that can lead to death at an early age.  An estimated 200,000 people in the United States and the Europe Union, and four to five million people worldwide, primarily in Latin America and Africa, are afflicted.  Currently, there is no universal cure for sickle cell disease. 

About Emmaus Medical, Inc.
Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase III clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine technology products. For more information, please visit www.emmausmedical.com and www.nutrestore.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding completion of the Phase III clinical trial in 2013, the potential for the L-Glutamine treatment for sickle cell disease, the timing, progress and anticipated results of the clinical development of the L-Glutamine treatment for sickle cell disease, Emmaus' ability to fund the development of the L-Glutamine treatment to completion, as well as Emmaus' plans and objectives. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the L-Glutamine treatment or any of our other product candidates, our ability to finance the development of our product candidates, regulatory risks, including our ability to obtain FDA, European Commission and other regulatory approval for L-Glutamine treatment for sickle-cell disease,  our ability to commercialize our L-Glutamine treatment for sickle cell disease, and our reliance on third party researchers and other collaborators. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2011. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Media:
Lori Teranishi for Emmaus Medical, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Matt Sheldon for Emmaus Medical, Inc.
310-279-5975
msheldon@pondel.com

Clinical Trial Information:
Dr. Henry Macan or Dr. Rafael Razon
310-214-0065
scdstudy@emmausmedical.com


'/>"/>
SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Medical Device Developers - Network at BIOMEDevice Boston Next Week
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
7. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
11. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):